[Inhibition of the metabolic and circulatory (cardiovascular) effects of diazoxide through alpha--and beta-receptor blockade].
D000236:Adenoma / Q000378:metabolism; D007516:Adenoma, Islet Cell / Q000378:metabolism; D000317:Adrenergic alpha-Antagonists; D000319:Adrenergic beta-Antagonists; D000941:Antigens; D001786:Blood Glucose / Q000378:metabolism; D001794:Blood Pressure / Q000187:drug effects; D002320:Cardiovascular Physiological Phenomena; D003981:Diazoxide / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D004336:Drug Antagonism; D005215:Fasting; D005230:Fatty Acids, Nonesterified / Q000097:blood; D005947:Glucose / Q000494:pharmacology; D005951:Glucose Tolerance Test; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D007328:Insulin / Q000097:blood / Q000378:metabolism; D000078790:Insulin Secretion; D007700:Kinetics; D010646:Phentolamine / Q000494:pharmacology*; D011433:Propranolol / Q000494:pharmacology*
D000317:Adrenergic alpha-Antagonists; D000319:Adrenergic beta-Antagonists; D000941:Antigens; D001786:Blood Glucose; D005230:Fatty Acids, Nonesterified; D007328:Insulin; D011433:Propranolol; D005947:Glucose; D003981:Diazoxide; D010646:Phentolamine
Hemmung der metabolischen und zirkulatorischen (kardiovaskulären) Diazoxid-Wirkung durch alpha-und beta-Rezeptorenblockade.